Description:Rabbit polyclonal antibody to Focal Adhesion Kinase (Phospho-Y576)Immunogen:KLH-conjugated synthetic phosphopeptide corresponding to residues surrounding Y576 of human Focal Adhesion Kinase protein. The exact sequence is proprietary.Purification:The antibody was purified by immunogen affinity chromatography.Clonality:PolyclonalForm:Liquid in 0.42% Potassium phosphate, 0.87% Sodium chloride, pH 7.3, 30% glycerol, and 0.01% sodium azide.Dilution:WB (1/500 - 1/1000)Gene Symbol:PTK2Alternative Names:FAK; FAK1; Focal adhesion kinase 1; FADK 1; Focal adhesion kinase-related nonkinase; FRNK; Protein phosphatase 1 regulatory subunit 71; PPP1R71; Protein-tyrosine kinase 2; p125FAK; pp125FAK
Entrez Gene (Human):
5747;
Entrez Gene (Mouse):
14083;
Entrez Gene (Rat):
25614;
SwissProt (Human):
Q05397;
SwissProt (Mouse):
P34152;
SwissProt (Rat):
O35346;
Storage/Stability:Shipped at 4°C. Upon delivery aliquot and store at -20°C for one year. Avoid freeze/thaw cycles.
-
Western blot analysis of Focal Adhesion Kinase (Phospho-Y576) expression in HEK293T Forskolin-treated (A), NIH3T3 Forskolin-treated (B), H9C2 Forskolin-treated (C) whole cell lysates. (Predicted band size: 119; 99; 63; 48; 120; 39; 114 kD; Observed band size: 125 kD)
Phase II trial of dasatinib in patients with metastatic breast cancer using real-time pharmacodynamic tissue biomarkers of Src inhibition to escalate dosing